INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
Portfolio Pulse from
Pomerantz LLP has filed a class action lawsuit against GSK regarding potential securities fraud related to the Zantac drug recall. In 2019, GSK suspended Zantac distribution after studies revealed the drug could create a carcinogenic compound. Deutsche Bank analysts suggested potential liability between $5-10 billion, which GSK later confirmed. The stock experienced price drops following these revelations.
March 21, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Class action lawsuit highlights potential securities fraud related to Zantac recall, with estimated liability between $1-10 billion potentially impacting investor confidence.
The lawsuit and potential massive liability directly impact GSK's financial standing, likely causing investor uncertainty and potential stock price depression.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100